- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01367366
Dx Mediastinal Malignant LAP:Compare PET and EBUS-TBNA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lung cancer ranks among the most commonly occurring malignancies and currently is the leading cause of cancer-related cause worldwide including Taiwan [1, 2]. Although a lot of research focus on the treatment of lung cancer, the prognosis of lung cancer remains dismal and a five year survival ate is less than 15% [3]. Unfortunately, early detection of lung cancer is still a problem. In a tertiary care hospital in Taiwan, only 27.3% of patients could received operation (stage I 15%, stage II 7.5%) [4]. Lymph node staging is also important for evaluation the possibility of operation.
Fluorodeoxyglucose-positron emission tomography (FDP-PET) is now used by oncologist to evaluate lung masses, solitary pulmonary nodules and intrathoracic lymph nodes. As the technique becomes more widespread, it is now used even as a first line imaging investigation. Although PET has a high negative predictive value, it is neither sensitive nor specific to differentiate benign from malignant mediastinal lymph nodes [5, 6]. If PET positive mediastinal lymph nodes are equal to malignant involvement, some patients might be excluded from potentially curative surgery. Several national guideline groups suggest that PET positive lymph nodes should be biopsied if it is likely that the result will alter clinical management [7, 8].
"Cervical mediastinoscopy" has been regarded as the "standard procedure" for sampling mediastinal lymph nodes. However, these techniques require general anesthesia and could not be repeated because of adhesion. Access to hilar nodal stations can be difficult for mediastinoscopy. In recent years, one minimally invasive method endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was used for biopsy of both hilar and mediastinal lymph nodes [9]. EBUS-TBNA allows the mediastinal lymph nodes to be targeted in the areas accessible to cervical mediastinoscopy, as well as some hilar nodes (lymph node stations 2-4, 7, 10-12)[9] .
Kazuhiro Yasufuku had published the first report of real-time EBUS-TBNA in evaluating mediastinal lymphadenopathy in 2004 [10]. Currently, the main indication of EBUS-TBNA is the mediastinal nodal staging of NSCLC after recent meta-analyses established the comparable sensitivity and specificity of nodal staging by EBUS-TBNA and cervical mediastinoscopy [11]. Efficacy in evaluation of other disease processes such as sarcoidosis and lymphoma has also been established [12].
Although there were several large studies to compare the diagnostic efficacy of mediastinal malignant lymphadenopathy between FDG-PET and EBUS-TBNA, the investigators need to have our own data because of high incidence of TB lymphadenitis in Taiwan, where the diagnostic accuracy of PET may be lower than other countries.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Chao-Chi Ho, PhD
- Phone Number: 886-972651317
- Email: ccho1203@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age older than 18 years
- Patient with suspected malignant mediastinal lymphadenopathy
Exclusion Criteria:
- Age younger than 18 years
- Bleeding diathesis(INR > 1.4, Platelet count < 10,000/mcl)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Mediastinal malignant lymphadenopathy
|
PET and EBUS-TBNA once, respectively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic value of PET and EBUS-TBNA
Time Frame: 1 week
|
Thg diagnostic criteria for malignant mediastinal lymphadenopathy is as followed:
The gold standard diagnostic method is surgical biopsy of the culprit lymph node. The sensitivity,specificity,positive and negative predictive value will be calculated. |
1 week
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chao-Chi Ho, PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201004018R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mediastinal Lymphadenopathy
-
Sanjay Gandhi Postgraduate Institute of Medical...CompletedMediastinal Lymphadenopathy | Hilar LymphadenopathyIndia
-
China-Japan Friendship HospitalNot yet recruitingLymphadenopathy Hilar | Lymphadenopathy Mediastinal
-
China-Japan Friendship HospitalRecruitingStudy on Transbronchial Ultrasound-guided Cryobiopsy in the Diagnosis of Mediastinal LymphadenopathyMediastinal LymphadenopathyChina
-
Third Military Medical UniversityHeidelberg UniversityCompletedMediastinal LymphadenopathyChina, Germany
-
Royal Brompton & Harefield NHS Foundation TrustUnknown
-
Hannover Medical SchoolUnknown
-
Northwell HealthCompletedMediastinal Lymphadenopathy | Lung MalignanciesUnited States
-
Baylor College of MedicineCompletedMediastinal Lymphadenopathies | Mediastinal Masses | Hilar LymphadenopathiesUnited States
-
National Taiwan University HospitalUnknownMediastinal Lymphadenopathy | Tuberculous Mediastinal LymphadenopathyTaiwan
-
Chang Gung Memorial HospitalUnknownLung Cancer | Mediastinal LymphadenopathyTaiwan
Clinical Trials on PET and EBUS-TBNA
-
St. Olavs HospitalNorwegian University of Science and TechnologyTerminated
-
National Cancer Center, KoreaWithdrawnNon Small Cell Lung CancerKorea, Republic of
-
Pulmonary Hospital ZakopaneCompletedNon-small Cell Lung CancerPoland
-
Heidelberg UniversityOlympus CorporationUnknown
-
China-Japan Friendship HospitalRecruitingStudy on Transbronchial Ultrasound-guided Cryobiopsy in the Diagnosis of Mediastinal LymphadenopathyMediastinal LymphadenopathyChina
-
Royal Brompton & Harefield NHS Foundation TrustOlympus CorporationCompletedLymphoma | Lung Cancer | Lymphadenopathy | SarcoidosisUnited Kingdom
-
University of CalgaryCompletedEBUS-TBNA Training MethodsCanada
-
Centre Hospitalier Universitaire Saint PierreSuspended
-
HealthPartners InstituteCompletedEnlarged Lymph Nodes (Excluding Infective)United States
-
University College London HospitalsUnknownLymphoma | Lung Cancer | Tuberculosis | Sarcoidosis | Isolated Mediastinal LymphadenopathyUnited Kingdom